Thoracic 18F-FDG PETCT
|
|
- Ashley Summers
- 8 years ago
- Views:
Transcription
1 Thoracic 18F-FDG PETCT RAD Magazine, 41, 482, Dr Allanah arker Specialist registrar radiology Dr Nagmi Qureshi Consultant cardiothoracic radiologist Papworth Hospital, Cambridge Introduction Positron emission tomography computed tomography (PETCT) is a hybrid imaging modality that provides both anatomical CT and functional PET information in a single study. In clinical practice the most widely used PET imaging tracer is the glucose analogue labelled positron emitter 18 F-Fluorodeoxyglucose (18F-FDG). FDG accumulates in cells that demonstrate increased glucose metabolism typically seen in malignant cells. Since its introduction in the 1990s, 18F-FDG PETCT has proven to be a valuable tool for diagnosis and staging of lung cancer. This article provides an overview of the current indications for thoracic PETCT and highlights potential limitations and pitfalls in image acquisition and interpretation. What are the indications for PETCT in thoracic practice? Staging of non-small cell lung cancer (NSCLC) Lung carcinoma is the leading cause of cancer-related death in the western world. In the UK there are over 39,000 new diagnoses of lung cancer per annum, accounting for 35,000 deaths. The majority of patients present with advanced disease and this, in part, accounts for the low long-term survival rate for lung cancer in the UK currently 5.5%. 1 The National Institute of Clinical Excellence (NICE) guidelines recommend that all patients suitable for treatment with curative intent by surgery, radical radiotherapy or chemoradiotherapy are staged using 18F-FDG PETCT. The main role for 18F-FDG PETCT in lung cancer staging is as a complementary tool alongside existing imaging and endoscopic modalities, which include contrast-enhanced CT, endobronchial ultrasound (EUS) and endoscopic ultrasound (EUS). 1 Accurate lung cancer staging using the seventh edition tumour (T), node (N), metastasis (M), classification system is essential because the detection of locally advanced or distant metastatic disease will influence treatment selection and is the main determinant of prognosis in NSCLC. 2 PETCT is particularly useful at detecting occult nodal and extra-thoracic metastasis not evident on the staging contrast enhanced CT (figure 1). A systematic review found that 18F-FDG PET detected 11%-20% more distant metastases than other imaging methods, resulting in a management change in 9%-64% of patients and reducing the incidence of futile thoracotomies from 41% to 21%. 3 The superior anatomic detail of helical CT means the T stage, tumour size and extent of tumour invasion is best assessed by contrast enhanced CT. PETCT plays a limited role in T staging due to its lower spatial resolution. However, it can complement CT by helping assess tumour extent and differentiating metabolically active primary tumour from distal collapse, which may be important for radiotherapy treatment planning. According to the current NICE guidelines, 18F-FDG PETCT is the preferred first test after CT in patients with mediastinal nodes <1cm short axis with low probability of mediastinal spread as well as nodes that measure 1-2cm on CT (intermediate probability of mediastinal spread) where there is curative intent. PETCT is not indicated for patients with high probability of mediastinal or distant metastatic disease. In this situation biopsy of the metastatic disease is recommended. 1 Reported sensitivity and specificities of 18F-FDG PETCT for metastatic lymph node staging range from 83%-100% and 78%-92% respectively, compared with 59%-61% and 79% respectively for CT alone. 4,5 Nevertheless, false negatives can occur due to micro-metastatic disease and false positives in patients with pulmonary fibrosis, vasculitis, infection/inflammation and granulomatous disease. Sarcoid-like reaction that corresponds to the presence of non-caseating granulomas in patients with solid malignancy is an increasingly recognised entity where there is avid FDG tracer uptake that can mimic nodal metastasis and can lead to over-staging (figure 2). Similarly, avid nodal FDG uptake is seen in patients with previous inhalational lung disease due to anthracotic pigment deposition in lymph nodes. In these situations, nodal sampling by mediastinoscopy or EUS is essential for accurate mediastinal staging. Therefore, current NICE guidelines recommend that mediastinal nodal sampling should be performed for all PET positive nodes, PET negative nodes that measure >1cm in short axis or for central tumours with positive hilar nodes on PETCT. Normal sized mediastinal nodes that show no tracer uptake on PETCT do not require further sampling. 1 Solitary pulmonary nodules Solitary pulmonary nodules (SPN) are defined as a discrete well-defined intra-parenchymal lesion <3cm in size. Current NICE guidelines suggest that 18F-FDG PETCT should be considered for all indeterminate SPNs identified on CT in patients of good performance status, especially where biopsy is considered technically difficult, where there is a significant risk of pneumothorax, or previous biopsy attempts have proved non-diagnostic. 1 False positives and false negatives Although malignant nodules usually show increased FDG uptake there is no reproducible standardised uptake value (SUV) that can confidently differentiate between a malignant and benign lesion. False positive results can occur in certain benign conditions including granulomatous disease (T and sarcoidosis) and infective/inflammatory conditions (figure 3). False negative results can be seen in tumours that demonstrate low glucose metabolism and include lung adenocarcinomas with a lepidic or mucinous component and carcinoid tumours that show no atypia (figure 4). Although the resolution of PET is continually improving, it remains 7-8mm and false negatives can occur in small malignant nodules that demonstrate low SUV due to partial volume effect rather than reflecting the underlying nature of the nodule. 6 In these situations findings should be interpreted with caution. Lesions thought to be low risk for malignancy may be followed by interval CT and those considered high risk for malignancy could be offered biopsy. The most recent meta-analysis that included 1,008 nod-
2 ules from 22 eligible studies reported a pooled sensitivity of 95% (95% CI: 93%-98%) and specificity 82% (95% CI: 77%- 88%) for 18F-FDG PET in SPN characterisation. This metaanalysis included only studies using dedicated PET imaging systems, as published reports on the incremental value of integrated PETCT systems are limited. 7 Other indications for PETCT in thoracic oncology Restaging NSCLC For patients with NSCLC treated with curative intent, the five-year survival rate is around 14%. 2 Local or distant disease recurrence is common and directly related to the tumour T and N stage at the time of surgery/radiotherapy as well as to the histologic type and the extent of resection. On CT it is often difficult to differentiate post-operative scarring or post-radiotherapy pneumonitis/fibrosis from disease recurrence. 18F-FDG PETCT can be helpful in these cases and has been shown to be more sensitive and specific than chest CT for detecting disease recurrence (90% and 90% and 78% and 80%, respectively). However, because postradiation/surgical related inflammatory change can cause avid FDG uptake and simulate tumour recurrence, repeat scanning should not be performed within three months of treatment. 8 Following stereotactic radiotherapy PETCT performed at 12 months rather than three months has been shown to be most accurate for detecting local recurrence. 9 Typically focal nodular tracer uptake is more suggestive of local recurrent disease compared to curvilinear uptake that is likely to represent inflammation. Small cell lung cancer (SCLC) SCLC is more aggressive than NSCLC and has a poorer prognosis. The role of PETCT in the diagnosis and staging of SCLC is limited. The Royal College of Radiology guidelines suggest using PETCT in the staging of patients who appear, on CT, to have limited disease being considered for radical treatment. 10 Investigation of pleural disease Currently in the UK, 18F-FDG PETCT is not routinely recommended in the diagnostic work-up of patients with malignant pleural mesothelioma. However, the Royal College of Radiologists and European Society of Medical Oncology guidelines suggest it should be considered to exclude extrathoracic disease in proven mesothelioma in patients being considered for multi-modality treatment including radical surgery/decortication. In addition, in patients with pleural thickening and suspected mesothelioma where conventional imaging and biopsy have been non-diagnostic or equivocal, there is some evidence that PETCT may be useful for guiding an optimal site to biopsy F-FDG PETCT is less likely to be useful in patients presenting with a pleural effusion only or with a history of previous pleurodesis. Talc pleurodesis can cause a chronic inflammatory reaction that may be FDG-avid and mimic pleural tumour deposits on PET in patients treated for pulmonary or pleural malignancy (figure 4). The characteristic high CT attenuation of talc density from matched FDG-avid curvi-linear features helps to differentiate this entity from pleural tumours. 10 Pulmonary artery sarcoma Pulmonary artery sarcoma (PAS) is an extremely rare neoplasm that is usually indistinguishable from acute or chronic thromboembolic disease of the pulmonary arteries on clinical and CT findings. The role of 18F-FDG PETCT in the diagnosis of PAS is still under investigation, although studies have suggested that moderate and high grade PAS usually demonstrate increased tracer uptake on PETCT. It should be noted that low grade myxoid PAS may not take up FDG, producing a false negative result. PETCT can also be used in assessing treatment response in high grade PAS. 13 General artifacts and normal variants One of the main problems with thoracic 18F-FDG PETCT interpretation is the presence of artifacts, normal variants and non-malignant physiological tracer uptake. In the chest, differences in breathing and timing acquisition of the PET and CT images (6-9 minutes/bed and tidal breathing for PET and around 15 seconds and deep inspiration for CT) can lead to image misregistration and potential misdiagnosis. This can be seen adjacent to the myocardium as well as around the diaphragm where hepatic metastasis may erroneously appear in the lung. Correlation with the staging CT scan is essential in this situation. Metallic objects within the body, such as stents, can also cause increased FDG uptake in adjacent tissue due to beam hardening related artifacts, potentially causing false positive results. Similarly, normal symmetrical, linear physiologic uptake in brown fat may show an asymmetrical distribution leading to potential errors in interpretation. 14 Conclusion PETCT has established itself as an invaluable complementary imaging modality for the evaluation of various thoracic conditions. Awareness of normal variants, potential false positives and negatives can significantly reduce misdiagnosis and improve diagnostic accuracy and image interpretation. References 1, Lung Cancer. NICE clinical guideline 121. April , Goldstraw P, Crowley J, Chansky K et al. The IASLC Lung Cancer Staging Project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007;2: , Fletcher J W, Djulbegovic, Soares H P et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med Mar 2008;49(3): , irim O, Kappetein A P, Stijnen T, ogers A J. Meta-analysis of positron emission tomographic and computed tomographic imaging in detecting mediastinal lymph node metastases in nonsmall cell lung cancer. Ann Thorac Surg 2005;79: , Gould M K, Kuschner W G, Rydzak C E et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: A meta-analysis. Ann Intern Med 2003;139(11): , Rohren E M, Turkington T G, Coleman R E. Clinical application of PET in oncology. Radiology 2004;231: , Cronin P, Dwamena A, Kelly A M, Carlos R C. Solitary pulmonary nodules: Meta-analytic comparison of cross-sectional imaging modalities for diagnosis of malignancy. Radiology 2008;246: , ury T, Corhay J L, Duysinx et al. Value of FDG-PET in detecting residual or recurrent nonsmall cell lung cancer. Eur Respir J 1999;14(6): , Hicks R J, Kalff V, MacManus M P et al. The utility of (18)F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: Impact on management and prognostic stratification. J Nucl Med 2001;42(11): , Evidence-based indications for the use of PET-CT in the UK , Stahel R A, Weder W, Lievens Y, Felip E, on behalf of the ESMO Guidelines Working Group. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 21 (Supplement 5): v126-v128, , Guidelines of European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignancy pleural mesothelioma. Eur Respir J 2010;35: , Wong H H, Gounaris I, McCormack A et al. Presentation and management of pulmonary artery sarcoma. Clin Sarcoma Res 2015;5(1):3. 14, Kligerman S, Digumarthy S. Staging of non-small cell lung cancer using integrated PET/CT. Am J Roentgenol 2009;193(5):
3 A Figure 1 (A) Axial contrast enhanced CT demonstrates a solitary right upper lobe 2.8cm nodule with adjacent pleural puckering in keeping with a suspected early stage T2aN0M0 lung cancer. () 18F-FDG PETCT coronal reformats show RUL nodule tracer uptake (Max SUV 5) (yellow arrow) and incidental focal tracer uptake (Max SUV 8) (white arrow) within the left pectoralis major muscle suggestive of an occult intramuscular metastasis. This upstaged the disease to T2aN0M1b. Figure 2 Sarcoid like reaction: (A) Axial CT shows a right lower lobe biopsy proven 8mm adenocarcinoma (red arrow) and symmetrical mediastinal and hilar adenopathy (blue arrows). () PETCT showed low grade tracer uptake (Max SUV 2.5) in the primary tumour (red arrow) and avid nodal uptake (Max SUV 15). EUS confirmed the presence of benign non-caseating nodal granulomas in keeping with a sarcoid-like reaction.
4 C Figure 3 Organising pneumonia leading to a false positive 18F-FDG PETCT: (A) Contrast enhanced CT shows a 5cm left upper lobe mass that extends into the mediastinum concerning for a localised primary lung cancer with avid tracer uptake Max SUV 6 on 18F-FDG PETCT. () CT guided biopsy was performed to obtain histological confirmation which demonstrated organising pneumonia and no evidence of malignancy. (C) Follow-up CT performed after two months and a short course of steroids/antibiotic with complete resolution of the inflammatory mass.
5 Figure 4 (A) 18F-FDG PETCT shows FDG avid right talc pleurodesis induced pleural masses with corresponding high attenuation talc on CT mimicking pleural malignancy. () In addition the scan demonstrated a 1.5cm part solid left apical lesion. This showed low-grade tracer uptake Max SUV 1.5 (arrow) and was initially wrongly reported as a focal area of benign scarring. Subsequent CT guided biopsy confirmed a lepidic primary lung adenocarcinoma causing a false negative 18F-FDG PETCT finding.
PET/CT in Lung Cancer
PET/CT in Lung Cancer Rodolfo Núñez Miller, M.D. Nuclear Medicine and Diagnostic Imaging Section Division of Human Health International Atomic Energy Agency Vienna, Austria GLOBOCAN 2012 #1 #3 FDG-PET/CT
More informationThe Need for Accurate Lung Cancer Staging
The Need for Accurate Lung Cancer Staging Peter Baik, DO Thoracic Surgery Cancer Treatment Centers of America Oklahoma Osteopathic Association 115th Annual Convention Financial Disclosures: None 2 Objectives
More informationMalignant Pleural Diseases Advances Clinicians Should Know F Gleeson
Malignant Pleural Diseases Advances Clinicians Should Know F Gleeson The following relevant disclosures, conflicts of interest and/ or financial relationships exist related to this presentation: Consultant
More informationFalse positive PET in lymphoma
False positive PET in lymphoma Thomas Krause Introduction and conclusion 2 3 Introduction 4 FDG-PET in staging of lymphoma 34 studies with 2227 Patients CT FDG-PET Sensitivity 63 % 89 % (58%-100%) (63%-100%)
More informationObjectives. Mylene T. Truong, MD. Malignant Pleural Mesothelioma Background
Imaging of Pleural Tumors Mylene T. Truong, MD Imaging of Pleural Tumours Mylene T. Truong, M. D. University of Texas M.D. Anderson Cancer Center, Houston, TX Objectives To review tumors involving the
More informationRole of FDG PET and PET/CT Imaging in Indeterminate Pulmonary Nodules and Lung Cancer
Role of FDG PET and PET/CT Imaging in Indeterminate Pulmonary Nodules and Lung Cancer Dominique Delbeke, MD, PhD Vanderbilt University Medical Center Nashville, Tennessee Congreso Chileno de Medicina Nuclear,
More informationRecommendations for cross-sectional imaging in cancer management, Second edition
www.rcr.ac.uk Recommendations for cross-sectional imaging in cancer management, Second edition Breast cancer Faculty of Clinical Radiology www.rcr.ac.uk Contents Breast cancer 2 Clinical background 2 Who
More informationPET POSITIVE PLEURAL PLAQUES DECADES AFTER PLEURODESIS: MESOLTHELIOMA? Ellen A. Middleton 1. Jonathan C. Daniel 2. Kenneth S.
PET POSITIVE PLEURAL PLAQUES DECADES AFTER PLEURODESIS: MESOLTHELIOMA? Ellen A. Middleton 1 Jonathan C. Daniel 2 Kenneth S. Knox 1 Kathleen Williams 1 Departments of Medicine 1 and Surgery 2, University
More informationPET. Can we afford PET-CT. Positron annihilation. PET-CT scanner. PET detection
PET-CT Can we afford PET-CT John Buscombe New technology Combines functional information-pet anatomical information-ct Machine able to perform both studies in single imaging episode PET imaging depends
More informationPET/CT: Basic Principles, Applications in Oncology
PET/CT: Basic Principles, Applications in Oncology Mabel Djang, HMS III Overview PET Basics and Limitations PET/CT - Advantages and Limitations Applications of PET/CT in oncology Summary 2 Principles of
More informationSMALL CELL LUNG CANCER
Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New
More informationA Practical Guide to Advances in Staging and Treatment of NSCLC
A Practical Guide to Advances in Staging and Treatment of NSCLC Robert J. Korst, M.D. Director, Thoracic Surgery Medical Director, The Blumenthal Cancer Center The Valley Hospital Objectives Revised staging
More informationElements of PET/CT Reporting
Elements of PET/CT Reporting 1. Clinical History a. Indication i. tumor type ii. abnormality to be evaluated iii. specific clinical question b. Relevent history i. biopsy results ii. chemotherapy iii.
More informationLung Cancer Treatment Guidelines
Updated June 2014 Derived and updated by consensus of members of the Providence Thoracic Oncology Program with the aid of evidence-based National Comprehensive Cancer Network (NCCN) national guidelines,
More informationGUIDELINES FOR THE MANAGEMENT OF LUNG CANCER
GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT
More informationTreatment Algorithms for the Management of Lung Cancer in NSW Guide for Clinicians
Treatment Algorithms for the Management of Lung Cancer in NSW Guide for Clinicians Background The Cancer Institute New South Wales Oncology Group Lung (NSWOG Lung) identified the need for the development
More informationDisease/Illness GUIDE TO ASBESTOS LUNG CANCER. What Is Asbestos Lung Cancer? www.simpsonmillar.co.uk Telephone 0844 858 3200
GUIDE TO ASBESTOS LUNG CANCER What Is Asbestos Lung Cancer? Like tobacco smoking, exposure to asbestos can result in the development of lung cancer. Similarly, the risk of developing asbestos induced lung
More informationPrimary -Benign - Malignant Secondary
TUMOURS OF THE LUNG Primary -Benign - Malignant Secondary The incidence of lung cancer has been increasing almost logarithmically and is now reaching epidemic levels. The overall cure rate is very low
More informationRadiation Therapy in the Treatment of
Lung Cancer Radiation Therapy in the Treatment of Lung Cancer JMAJ 46(12): 537 541, 2003 Kazushige HAYAKAWA Professor and Chairman, Department of Radiology, Kitasato University School of Medicine Abstract:
More informationPost-recurrence survival in completely resected stage I non-small cell lung cancer with local recurrence
Post- survival in completely resected stage I non-small cell lung cancer with local J-J Hung, 1,2,3 W-H Hsu, 3 C-C Hsieh, 3 B-S Huang, 3 M-H Huang, 3 J-S Liu, 2 Y-C Wu 3 See Editorial, p 185 c A supplementary
More informationNICE Pathways bring together all NICE guidance, quality standards and other NICE information on a specific topic.
bring together all NICE guidance, quality standards and other NICE information on a specific topic. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published.
More informationSurgeons Role in Symptom Management. A/Prof Cliff K. C. Choong Consultant Thoracic Surgeon Latrobe Regional Hospital GIPPSLAND
Surgeons Role in Symptom Management A/Prof Cliff K. C. Choong Consultant Thoracic Surgeon Latrobe Regional Hospital GIPPSLAND Conditions PLEURAL Pleural effusion Pneumothorax ENDOBRONCHIAL Haemoptysis
More informationInterview with David Djang, MD On PET Scan in Oncology: Principles and Practice
Interview with David Djang, MD On PET Scan in Oncology: Principles and Practice By Howard (Jack) West, MD May, 2009 Hello and welcome to the GRACE audio podcast on PET scanning. This one is with Dr. David
More informationDetection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical
Summary. 111 Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical recurrence (BCR) is the first sign of recurrent
More informationPractice Guidelines in Oncology. A summary of the recommendations and practice guidelines of professional groups. April 2013 EXECUTIVE SUMMARY
18 F-fluorodeoxyglucose (FDG) PET and PET/CT Practice Guidelines in Oncology A summary of the recommendations and practice guidelines of professional groups April 2013 The recommendations and practice
More informationLung cancer is not just one disease. There are two main types of lung cancer:
1. What is lung cancer? 2. How common is lung cancer? 3. What are the risk factors for lung cancer? 4. What are the signs and symptoms of lung cancer? 5. How is lung cancer diagnosed? 6. What are the available
More informationTable of Contents. Data Supplement 1: Summary of ASTRO Guideline Statements. Data Supplement 2: Definition of Terms
Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation
More informationManagement of Non-Small Cell Lung Cancer Guide for General Practitioners
Management of n-small Cell Lung Cancer Guide for General Practitioners Clinical Stage I Cancer only in one lobe of lung and
More informationPET/CT in Breast Cancer
PET/CT in Breast Cancer Rodolfo Núñez Miller, M.D. Nuclear Medicine and Diagnostic Imaging Section Division of Human Health International Atomic Energy Agency Vienna, Austria Overview Introduction Locorregional
More informationMale. Female. Death rates from lung cancer in USA
Male Female Death rates from lung cancer in USA Smoking represents an interesting combination of an entrenched industry and a clearly drug-induced cancer Tobacco Use in the US, 1900-2000 5000 100 Per Capita
More informationMetastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases.
Metastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases. Abstract This paper describes the staging, imaging, treatment, and prognosis of renal cell carcinoma. Three case studies
More informationInternational Journal of Case Reports in Medicine
International Journal of Case Reports in Medicine Vol. 2013 (2013), Article ID 409830, 15 minipages. DOI:10.5171/2013.409830 www.ibimapublishing.com Copyright 2013 Andrew Thomas Low, Iain Smith and Simon
More informationMesothelioma. 1. Introduction. 1.1 General Information and Aetiology
Mesothelioma 1. Introduction 1.1 General Information and Aetiology Mesotheliomas are tumours that arise from the mesothelial cells of the pleura, peritoneum, pericardium or tunica vaginalis [1]. Most are
More informationSmall Cell Lung Cancer
Small Cell Lung Cancer Types of Lung Cancer Non-small cell carcinoma (NSCC) (87%) Adenocarcinoma (38%) Squamous cell (20%) Large cell (5%) Small cell carcinoma (13%) Small cell lung cancer is virtually
More informationLow-dose CT Imaging. Edgar Fearnow, M.D. Section Chief, Computed Tomography, Lancaster General Hospital
Lung Cancer Screening with Low-dose CT Imaging Edgar Fearnow, M.D. Section Chief, Computed Tomography, Lancaster General Hospital Despite recent declines in the incidence of lung cancer related to the
More informationExtrapleural Pneumonectomy for Malignant Mesothelioma: Pro. Joon H. Lee 9/17/2012
Extrapleural Pneumonectomy for Malignant Mesothelioma: Pro Joon H. Lee 9/17/2012 Malignant Pleural Mesothelioma (Epidemiology) Incidence: 7/mil (Japan) to 40/mil (Australia) Attributed secondary to asbestos
More informationIn the last hundred years, lung cancer has risen from a
CONTINUING EDUCATION PET Evaluation of Lung Cancer* Tira Bunyaviroch, MD 1 ; and R. Edward Coleman, MD 2 1 Boston University School of Medicine and Boston Medical Center, Boston, Massachusetts; and 2 Duke
More informationGuidelines on the radical management of patients with lung cancer A Quick Reference Guide
ISSN 2040-2023 October 2010 Guidelines on the radical management of patients with lung cancer A Quick Reference Guide British Thoracic Society GUIDELINES ON THE RADICAL MANAGEMENT OF PATIENTS WITH LUNG
More informationThe National Clinical Lung Cancer Audit (LUCADA)
The National Clinical Lung Cancer Audit (LUCADA) DATA MANUAL Title: Version: 3.1.5 Date: September 2013 LUCADA Lung Cancer Audit VERSION HISTORY Version Date Issued Brief Summary of Change Owner s Name
More informationPatterns of nodal spread in thoracic malignancies
Patterns of nodal spread in thoracic malignancies Poster No.: C-0977 Congress: ECR 2010 Type: Educational Exhibit Topic: Chest Authors: R. dos Santos, M. Duarte, J. Alpendre, J. Castaño, Z. Seabra, Â.
More informationThis factsheet aims to outline the characteristics of some rare lung cancers, and highlight where each type of lung cancer may be different.
There are several different kinds of lung cancer, often referred to as lung cancer subtypes. Some of these occur more often than others. In this factsheet we will specifically look at the subtypes of cancers
More informationHow To Know When To Stage Lung Cancer
WHITE PAPER - SBRT for Non Small Cell Lung Cancer I. Introduction This white paper will focus on non-small cell lung carcinoma with sections one though six comprising a general review of lung cancer from
More informationCase Report: Whole-body Oncologic Imaging with syngo TimCT
Case Report: Whole-body Oncologic Imaging with syngo TimCT Eric Hatfield, M.D. 1 ; Agus Priatna, Ph.D. 2 ; John Kotyk, Ph.D. 1 ; Benjamin Tan, M.D. 1 ; Alto Stemmer 3 ; Stephan Kannengiesser, Ph.D. 3 ;
More informationGuideline for the Referral, Diagnosis and Staging of Patients with Lung Cancer
Guideline for the Referral, Diagnosis and Staging of Patients with Lung Cancer Incorporating: Guideline for the diagnosis and staging of patients with lung cancer detected within secondary care, guidelines
More informationLung cancer forms in tissues of the lung, usually in the cells lining air passages.
Scan for mobile link. Lung Cancer Lung cancer usually forms in the tissue cells lining the air passages within the lungs. The two main types are small-cell lung cancer (usually found in cigarette smokers)
More informationPET-CT in the assessment of lung cancer at Rikshospitalet from 2007 2011938 44
Original article in the assessment of lung cancer at Rikshospitalet from 2007 2011938 44 BACKGROUND is an aid in the assessment of lung cancer for identifying operable patients. The examination is recommended
More informationLUNG CANCER SCREENING: UNDERSTANDING LUNG NODULES. 1-800-298-2436 LungCancerAlliance.org
LUNG CANCER SCREENING: UNDERSTANDING LUNG NODULES 1-800-298-2436 LungCancerAlliance.org 1 1 CONTENTS What is a Nodule?...3 Finding Nodules...4 If a Nodule Is Found...5 What Happens Next?...7 Questions
More informationContinuing Medical Education Article Imaging of Multiple Myeloma and Related Plasma Cell Dyscrasias JNM, July 2012, Volume 53, Number 7
Continuing Medical Education Article Imaging of Multiple Myeloma and Related Plasma Cell Dyscrasias JNM, July 2012, Volume 53, Number 7 Authors Ronald C. Walker 1,2, Tracy L. Brown 3, Laurie B. Jones-Jackson
More informationAvastin: Glossary of key terms
Avastin: Glossary of key terms Adenocarcinoma Adenoma Adjuvant therapy Angiogenesis Anti-angiogenics Antibody Antigen Avastin (bevacizumab) Benign A form of carcinoma that originates in glandular tissue.
More informationSurvival analysis of 220 patients with completely resected stage II non small cell lung cancer
窑 Original Article 窑 Chinese Journal of Cancer Survival analysis of 22 patients with completely resected stage II non small cell lung cancer Yun Dai,2,3, Xiao Dong Su,2,3, Hao Long,2,3, Peng Lin,2,3, Jian
More informationIAEA HumAn HEAltH SErIES
IAEA HumAn HEAltH SErIES no. 9 Appropriate Use of FDG-PET for the Management of Cancer Patients IAEA HUMAN HEALTH SERIES PUBLICATIONS The mandate of the IAEA human health programme originates from Article
More informationL Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer
Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine and systemic chemotherapy in malignant pleural mesothelioma. A 10-year experience. L Lang-Lazdunski, A Bille, S Marshall, R Lal,
More informationNon-small cell lung cancer (NSCLC) accounts for approximately
Diagn Interv Radiol 2012; 18:435 440 Turkish Society of Radiology 2012 CHEST IMAGING ORIGINAL ARTICLE Contrast enhanced CT versus integrated PET-CT in pre-operative nodal staging of non-small cell lung
More informationPET/CT in Lymphoma. Ur Metser, M.D. Division Head, Molecular Imaging Joint Department of Medical Imaging, UHN- MSH- WCH University of Toronto
PET/CT in Lymphoma Ur Metser, M.D. Division Head, Molecular Imaging Joint Department of Medical Imaging, UHN- MSH- WCH University of Toronto Outline 1. Introduction: PET/CT, how does it work? 2.Current
More informationNeoplasms of the LUNG and PLEURA
Neoplasms of the LUNG and PLEURA 2015-2016 FCDS Educational Webcast Series Steven Peace, BS, CTR September 19, 2015 2015 Focus o Anatomy o SSS 2000 o MPH Rules o AJCC TNM 1 Case 1 Case Vignette HISTORY:
More informationOBJECTIVES By the end of this segment, the community participant will be able to:
Cancer 101: Cancer Diagnosis and Staging Linda U. Krebs, RN, PhD, AOCN, FAAN OCEAN Native Navigators and the Cancer Continuum (NNACC) (NCMHD R24MD002811) Cancer 101: Diagnosis & Staging (Watanabe-Galloway
More informationINTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER Prospective Mesothelioma Staging Project
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER Prospective Mesothelioma Staging Project Data Forms and Fields in CRAB Electronic Data Capture System - Reduced Set - Pivotal data elements for developing
More informationCardiac Masses and Tumors
Cardiac Masses and Tumors Question: What is the diagnosis? A. Aortic valve myxoma B. Papillary fibroelastoma C. Vegetation from Infective endocarditis D. Thrombus in transit E. None of the above Answer:
More information2011 Radiology Diagnosis Coding Update Questions and Answers
2011 Radiology Diagnosis Coding Update Questions and Answers How can we subscribe to the Coding Clinic for ICD-9 guidelines and updates? The American Hospital Association publishes this quarterly newsletter.
More informationUnderstanding Your Surgical Options for Lung Cancer
Information Booklet for Patients Understanding Your Surgical Options for Lung Cancer Understanding Lung Cancer If you have just been diagnosed with lung cancer, this booklet will serve as an informational
More informationChanges in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain
Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain Second Opinion in Breast Pathology Usually requested when a patient is referred
More informationUNDERSTANDING SERIES LUNG NODULES. 1-800-298-2436 LungCancerAlliance.org
UNDERSTANDING SERIES LUNG NODULES 1-800-298-2436 LungCancerAlliance.org CONTENTS What is a Nodule?...2 Finding Nodules...3 If a Nodule is Found... 4 What Happens Next?...6 Questions to Ask about Your Results...7
More informationYOUR LUNG CANCER PATHOLOGY REPORT
UNDERSTANDING YOUR LUNG CANCER PATHOLOGY REPORT 1-800-298-2436 LungCancerAlliance.org A GUIDE FOR THE PATIENT 1 CONTENTS What is a Pathology Report?...3 The Basics...4 Sections of a Pathology Report...7
More informationTable of Contents: Chapter 1: Screening for breast cancer in asymptomatic patients by Chris Comstock, MD and Marie Tartar, MD
Table of Contents: Chapter 1: Screening for breast cancer in asymptomatic patients by Chris Comstock, MD and Marie Tartar, MD Case 1: Breast cancer presenting as a small new mass on Case 2: Breast cancer
More informationLocoregional recurrence or persistence of papillary carcinoma: radioiodine treatment
Locoregional recurrence or persistence of papillary carcinoma: radioiodine treatment Michele Klain, Marco Salvatore Department of Functional and Biomorphological Science University of Naples "Federico
More informationLung cancer. Lung cancer: English
Lung cancer: English Lung cancer This fact sheet is about how lung cancer is diagnosed and treated. We also have fact sheets in your language about chemotherapy, radiotherapy, surgery, side effects of
More informationInvasive Mediastinal Staging of Non-small Cell Lung Cancer
Evidence-Based Series 17-6 A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario Invasive Mediastinal Staging of Non-small Cell Lung Cancer G. Darling, J. Dickie, R. Malthaner,
More informationLung Cancer & Mesothelioma 2011-2015
Lung Cancer & Mesothelioma 2011-2015 Annex G Mesothelioma 1. The vision for mesothelioma services is set out in the Mesothelioma Framework issued by DH on 26 February 2007 (supported by the British Thoracic
More information3.0 With final Comments for presentation at Sub Group Meeting 24. 24.11.10
Guideline for the Treatment of Lung Cancer Version History 2.0 Endorsed by the Governance Committee as treatment of lung cancer 27.07.09 with radiotherapy and chemotherapy. 2.1 Re-written to include the
More informationHow To Treat Lung Cancer At Cleveland Clinic
Treatment Guide Lung Cancer Management The Chest Cancer Center at Cleveland Clinic, which includes specialists from the Respiratory Institute, Taussig Cancer Institute and Miller Family Heart & Vascular
More informationThe New International Staging System Lung Cancer
The New International Staging System Lung Cancer Valerie W. Rusch, MD Chief, Thoracic Surgery Memorial Sloan-Kettering Cancer Center Chair, Lung and Esophagus Task Force, American Joint Commission on Cancer
More informationHERC Coverage Guidance Advanced Imaging for Staging of Prostate Cancer Disposition of Public Comments
Table of Contents Commenters... 1 Public Comments... 2 References Provided by Commenters... 6 Commenters Identification Stakeholder A Medical Imaging & Technology Alliance (MITA), Arlington, VA [Submitted
More informationLung Cancer: An Overview
VOL. I Issue 2 2010 Lung Cancer: An Overview By Matthew F. Koscielski, M.D. Lung cancer is the most common cause of cancer mortality worldwide. In the United States there are about 220,000 new cases of
More informationLung Cancer Treatment
Scan for mobile link. Lung Cancer Treatment Lung cancer overview More than one in four of all diagnosed cancers involve the lung, and lung cancer remains the most common cancer-related cause of death among
More informationStage I Non-Small Cell Lung Cancer: Recurrence Patterns, Prognostic Factors and Survival
16 Stage I Non-Small Cell Lung Cancer: Recurrence Patterns, Prognostic Factors and Survival Jung-Jyh Hung and Yu-Chung Wu Division of Thoracic Surgery, Department of Surgery, Taipei Veterans General Hospital
More informationAn Update on Lung Cancer Diagnosis
An Update on Lung Cancer Diagnosis Dr Michael Fanning MBBS FRACGP FRACP RESPIRATORY AND SLEEP PHYSICIAN Mater Medical Centre Outline Risk factors for lung cancer Screening for lung cancer Radiologic follow-up
More informationPrognostic stratification of patients with T3N1M0 non-small cell lung cancer: which phase should it be?
DOI 10.1007/s12032-011-9907-y ORIGINAL PAPER Prognostic stratification of patients with T3N1M0 non-small cell lung cancer: which phase should it be? Ali Kilicgun Ozgur Tanriverdi Akif Turna Muzaffer Metin
More informationMulti-slice Helical CT Scanning of the Chest
Multi-slice Helical CT Scanning of the Chest Comparison of different low-dose acquisitions Lung cancer is the main cause of deaths due to cancer in human males and the incidence is constantly increasing.
More informationGeneral Information About Non-Small Cell Lung Cancer
General Information About Non-Small Cell Lung Cancer Non-small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. The lungs are a pair of cone-shaped breathing
More informationLung cancer case study
Change Presentation title and date in Footer dd.mm.yyyy Lung cancer case study Dr Jaishree Bhosle Consultant Medical Oncologist Change Presentation title and date in Footer dd.mm.yyyy 1 2 Part One Initial
More informationGuideline for the Imaging of Patients Presenting with Breast Symptoms incorporating the guideline for the use of MRI in breast cancer
Guideline for the Imaging of Patients Presenting with Breast Symptoms incorporating the guideline for the use of MRI in breast cancer Version History Version Date Summary of Change/Process 0.1 09.01.11
More informationSternotomy and removal of the tumor
Sternotomy and removal of the tumor All thymomas originate from epithelial thymic cells 4% of them consist of a pure population of epithelial cells Most have mixed populations of lymphoid cells to a
More informationNon-Small Cell Lung Cancer
Non-Small Cell Lung Cancer About Your Lungs and Lung Cancer How do your lungs work? To understand lung cancer it is helpful to understand your lungs. Your lungs put oxygen into the blood, which the heart
More informationMalignant Mesothelioma Current Approaches to a Difficult Problem. Raja M Flores, MD Thoracic Surgery Memorial Sloan-Kettering Cancer Center
Malignant Mesothelioma Current Approaches to a Difficult Problem Raja M Flores, MD Thoracic Surgery Memorial Sloan-Kettering Cancer Center Malignant Pleural Mesothelioma Clinical Presentation Insidious
More informationTreating Thyroid Cancer using I-131 Maximum Tolerable Dose Method
Treating Thyroid Cancer using I-131 Maximum Tolerable Dose Method Christopher Martel, M.Sc., CHP Lisa Thornhill,, NRRPT, RT(NM) Boston University Medical Center Thyroid Carcinoma New cases and deaths in
More informationBREATHE EASY HOW RADIOLOGY HELPS TO FIND AND FIGHT LUNG DISEASES
BREATHE EASY HOW RADIOLOGY HELPS TO FIND AND FIGHT LUNG DISEASES TABLE OF CONTENTS 3 BREATHE EASY TABLE OF CONTENTS 4 INTRODUCTION: AN OVERVIEW OF CHEST IMAGING 9 CHAPTER 1: Lung imaging: the techniques
More informationMedullary Renal Cell Carcinoma Case Report
Bahrain Medical Bulletin, Vol. 27, No. 4, December 2005 Medullary Renal Cell Carcinoma Case Report Mohammed Abdulla Al-Tantawi MBBCH, CABS* Abdul Amir Issa MBBCH, CABS*** Mohammed Abdulla MBBCH, CABS**
More informationبسم هللا الرحمن الرحيم
بسم هللا الرحمن الرحيم Updates in Mesothelioma By Samieh Amer, MD Professor of Cardiothoracic Surgery Faculty of Medicine, Cairo University History Wagner and his colleagues (1960) 33 cases of mesothelioma
More informationThe UK Inflammatory Breast Cancer Research Programme
The UK Inflammatory Breast Cancer Research Programme BSBR Research Afternoon November 2015 Sarah Vinnicombe and Fedor Berditchevski Introduction Inflammatory breast cancer (IBC) is rare 2.5% all cases
More informationRIJKSUNIVERSITEIT GRONINGEN. Thoracic masses From chest radiography and ultrasound guided biopsies to molecular biology.
RIJKSUNIVERSITEIT GRONINGEN Thoracic masses From chest radiography and ultrasound guided biopsies to molecular biology Proefschrift ter verkrijging van het doctoraat in de Medische Wetenschappen aan de
More informationKidney Cancer OVERVIEW
Kidney Cancer OVERVIEW Kidney cancer is the third most common genitourinary cancer in adults. There are approximately 54,000 new cancer cases each year in the United States, and the incidence of kidney
More informationPancreatic Cancer. The Killer that must be discovered early. Dr Alfred Kow Wei Chieh
Pancreatic Cancer The Killer that must be discovered early 27 th June 2015 Dr Alfred Kow Wei Chieh Consultant Department of Surgery Division of HPB Surgery & Liver Transplantation & Assistant Dean (Education)
More informationReport series: General cancer information
Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for
More informationNon-Small Cell Lung Cancer Treatment Comparison to NCCN Guidelines
Non-Small Cell Lung Cancer Treatment Comparison to NCCN Guidelines April 2008 (presented at 6/12/08 cancer committee meeting) By Shelly Smits, RHIT, CCS, CTR Conclusions by Dr. Ian Thompson, MD Dr. James
More informationWhat is the best way to diagnose and stage malignant pleural mesothelioma?
doi:10.1510/icvts.2010.255893 Interactive CardioVascular and Thoracic Surgery 12 (2011) 254 259 Best evidence topic - Thoracic oncologic What is the best way to diagnose and stage malignant pleural mesothelioma?
More informationa commitment in their practice to the roles and responsibilities of clinical oncologists X
CLINICAL ONCOLOGY BLUEPRINT OF ASSESSMENT SYSTEM Good Medical Practice areas of curriculum - ST5 (Intermediate) Standards GMP criterion Workplace based assessment By the end of the third year of training
More informationSUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD
SUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD Case Presentation 35 year old male referred from PMD with an asymptomatic palpable right neck mass PMH/PSH:
More information